

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

Information for the public

Published: 28 June 2017

www.nice.org.uk

Ponatinib (Iclusig) is available on the NHS.

It is a possible treatment for chronic-, accelerated- or blast-phase chronic myeloid leukaemia in adults:

- who can't have dasatinib or nilotinib or whose disease is resistant to them or
- who can't have subsequent treatment with imatinib or
- who have the T315I gene mutation.

It is also a possible treatment for Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults:

- who can't have dasatinib or whose disease is resistant to it or
- who can't have subsequent treatment with imatinib or
- who have the T315I gene mutation.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Leukaemia Care](#), 08088 010 444
- [Leukaemia Cancer Society](#), 0208 374 4821
- [Bloodwise](#) (previously Leukaemia & Lymphoma Research), 0808 2080 888
- [Cancer Research UK Patient Information](#) (previously CancerHelp UK), 0808 800 4040
- [Macmillan](#), 0808 808 0000

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2563-6